4 1 a34584.txt MICHAEL KANTOR Form 4 Page 1 of 2 ---------------------------- --------------- OMB APPROVAL FORM 4 ---------------------------- --------------- OMB Number: 3235-0287 ---------------------------- Expires: January 31, 2005 ---------------------------- Estimated average burden hours per response... 0.5 ---------------------------- [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

------------------------------------------------------------------------------------------------------------------------ 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol Kantor, Michael Pharmacia Corporation PHA ------------------------------------------------------------------------------------------------------------------------ (Last) (First) (Middle) 3. I.R.S. Identification 4. Statement for Number of Reporting Month/Day/Year Person, if an entity (voluntary) April 16, 2003 100 Route 206 North ------------------------------------------------------------------------------------------------------------------------ (Street) 5. If Amendment, Date of Original (Month/Day/Year) Peapack, NJ 07977 ------------------------------------------------------------------------------------------------------------------------ (City) (State) (Zip)

~~FORM~~--------------------------------------------------------------- 46. ~~[__]~~Relationship ~~Check~~of ~~this~~Reporting ~~box~~Person(s) ~~if no longersubject~~ to ~~Section~~Issuer ~~16.~~(Check ~~Form~~all 4applicable) orX ~~Form5~~Director ~~obligations~~10% ~~may~~Owner ~~continue.~~-------- ~~See~~------- ~~Instruction~~Officer 1(~~b).~~give Other (~~Print~~specify or-------- ~~Type~~title ~~Responses~~below) ~~UNITED~~------- ~~STATES~~below) ~~SECURITIES~~--------------------------------------------------------------- ~~AND EXCHANGE COMMISSION Washington, D~~7.C. ~~20549~~Individual ~~STATEMENT~~or OFJoint/Group ~~CHANGES~~Filing ~~IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16~~(a)Check ofApplicable ~~the Securities Exchange Act of 1934, Section 17(a~~Line) ofX ~~the~~Form ~~Public~~filed ~~Utility~~by ~~Holding~~One ~~Company~~Reporting ~~Act~~Person of------ ~~1935~~Form orfiled ~~Section~~by ~~30(h)~~More ofthan ~~the~~One ~~Investment~~Reporting ~~Company~~Person ~~Act of 1940 OMB APPROVAL OMB Number: 3235~~-~~0287~~----- ~~Expires: January 31, 2005Estimated average burdenhours per response. . . . . 0.5~~---------------------------------------------------------------

1.-------------------------------------------------------------------------------------------------------------------------- ~~Name~~Table ~~and~~I ~~Address~~- ofNon-Derivative ~~Reporting~~Securities Person*Acquired, ~~Needleman~~Disposed of, ~~Philip~~or ~~(Last)~~Beneficially ~~(First)~~Owned ~~(Middle)~~-------------------------------------------------------------------------------------------------------------------------- ~~100~~1. ~~Route~~Title ~~206~~of ~~North~~Security ~~(Street)~~2. ~~Peapack,~~Transaction NJDate ~~07977~~2A. Deemed 3. Transaction 4. Securities Acquired (~~City~~A) (~~State~~Instr. 3) (~~Zip~~Month/Day/Year) 2.Execution ~~Issuer~~Code ~~Name and Ticker~~ or ~~Trading~~Disposed ~~Symbol~~of ~~Pharmacia~~(D) -Date, ~~PHA 3~~(Instr.8) I(Instr.~~R.S.~~ ~~Identification Number of Reporting Person~~3, if4 anand ~~entity (voluntary~~5) 4.if ~~Statement~~any ~~for~~--------------------------------------------------------- (Month/~~Day/Year)~~ ~~01/02/2002~~Code 5.V IfAmount ~~Amendment,~~(A) ~~Date~~or ofPrice ~~Original (Month/~~Day/ (D) Year) 6.-------------------------------------------------------------------------------------------------------------------------- ~~Relationship~~Common of04/16/2003 ~~Reporting Person~~J(s1) to9,000 ~~Issuer~~D ~~(Check~~-------------------------------------------------------------------------------------------------------------------------- ~~all~~-------------------------------------------------------------------------------------------------------------------------- ~~applicable)~~-------------------------------------------------------------------------------------------------------------------------- __-------------------------------------------------------------------------------------------------------------------------- ~~Director~~-------------------------------------------------------------------------------------------------------------------------- __------------------------------------------------------------------------------------ ~~10%~~5. ~~Owner~~Amount Xof ~~Officer~~6. ~~(give~~Ownership ~~title~~7. ~~below)~~Nature __of ~~Other~~Securities ~~(specify~~Form: ~~below)~~Direct ~~Senior~~Indirect ~~Executive~~Beneficially ~~Vice~~(D) ~~President~~or 7.Indirect ~~Individual~~(I) orBeneficial ~~Joint/Group~~Owned ~~Filing~~Following (~~Check~~Instr. ~~Applicable Line~~4) _Ownership XReported _Transaction(s) ~~Form~~(Instr. ~~filed~~4) by(Instr. ~~One~~3 ~~Reporting~~and ~~Person~~4) ~~____~~------------------------------------------------------------------------------------ ~~Form~~0 ~~filed~~D by------------------------------------------------------------------------------------ ~~More~~------------------------------------------------------------------------------------ ~~than~~------------------------------------------------------------------------------------ ~~One~~------------------------------------------------------------------------------------ ~~Reporting Person~~------------------------------------------------------------------------------------

Form 4 Page 2 of 2 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) -------------------------------------------------------------------------------------------------------------------- 1. Title of Derivative 2. Conver- 3. Trans- 3A. Deemed Execution 4. Transac- 5. Number of Security (Instr. 3) sion or action Date, if any tion Code Derivative Exercise Date (Month/Day/Year) (Instr. 8) Securities Price of (Month/ Acquired (A) Derivative Day/ or Disposed of Security Year) (D) (Instr. 3, 4 and 5) ----------------------------------- Code V (A) (D) -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $41.92 04/16/2003 J(1) 23,027 -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------

~~Table~~------------------------------------------------------------------------------------------- I6. -Date ~~Non-~~Exercisable 7. Title and Amount of 8. Price of 9. Number of and Expiration Date Underlying Securities Derivative Derivative (Month/Day/Year) (Instr. 3 and 4) Security Securities ~~Acquired,~~(Instr. ~~Disposed~~5) Beneficially Owned Following Reported Transaction(s) (Instr. 4) ------------------------ --------------------------- Date Expi- Title Amount or Exercis- ration Number of able Date Shares ------------------------------------------------------------------------------------------- (2) 11/20/2007 Common 23,027 or0 ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------ 10. Ownership 11. Nature Form of of Indirect Derivative Beneficial Securities Ownership Beneficially (Instr. 4) Owned at End of Month (Instr. 4) ----------------------------------- D ----------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- -----------------------------------

Explanation of Responses: (1) Each share of Pharmacia Common Stock (PHA) held by the reporting person was exchanged for 1.4 shares of Pfizer Common Stock (PFE), pursuant to the Pfizer/Pharmacia merger agreement adopted by the Pfizer and Pharmacia shareholders on December 6 & 9, 2002, respectively. (2) Option is currently exercisable. /s/ Don W. Schmitz April 16, 2003 -------------------------------- ----------------- **Signature of Reporting Person Date Don W. Schmitz, attorney-in-fact for Michael Kantor Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. *If the form is filed by more than one reporting person, see Instruction 4(b)(v). **Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conver- sion or Exercise Price of Deri- vative Security

3. Transaction Date (Month/ Day/ Year)

3A. Deemed Execution Date, if any (Month/ Day/ Year)

4. Transaction Code (Instr.8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Securities: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

DateExercisable

ExpirationDate

Title

Amount orNumber ofShares

Phantom Stock Units

1 for 1

01/02/2002

42,870

//(1)

//(2)

Common

42,870

45,977 (3)

Explanation of Responses: (1) At the end of each calendar year 2002, 2003 and 2004, 1/3 of the units will be eligible for allocation based on Company performance for that year. (2) Distribution under the plan commences the calendar year following retirement, termination, death or disability, based on the provisions of the Savings+Plus deferred compensation plan. (3) Includes dividends accrued in the form of phantom stock units.
/s/ Don W. Schmitz for Philip Needleman	04/10/2003
** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Filing Compare · PHARMACIA CORP /DE/